|Structural diagram of (rapamycin). Created using ACD/ChemSketch 10.0 and . (Photo credit: Wikipedia)|
"An innovative clinical trial set to begin in March may resolve some of these issues. Kaeberlein and his University of Washington colleague Daniel Promislow plan to test the drug in small doses in middle-aged pet dogs. Rather than looking at life span, which would take years, they will look for signs that the drug is affecting key aging-related parameters, such as arterial stiffness and cardiac function. If successful, rapamycin and its derivatives could end up as the first anti-aging drug—for dogs. Kaeberlein wouldn’t mind: “I love my dogs,” he says. “If there’s anything we can do to make them live longer, healthier lives, we have to do it. I feel like I personally have to do this.”"
'via Blog this'
Return Home: The Health, Drug, Prescription, and GMP Supersite Blog
SkillsPlus Intl Inc. - The best GMP training, best QSR training, best instructors
cGMP Mini-Series - Short Videos for GMP Trainer Use
SkillsPlus Intl Info Blog
The Designated Rep and Exemptee Professionals Blog
The Health, Drug, Prescription, and GMP Supersite Gift Store